Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan

Anish Patel, COO of Enliven Therapeutics, sold shares of common stock on April 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, sold shares of the company's common stock on April 8, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 29, 2023.
• A total of 4,875 shares were sold in two separate transactions.
• The first transaction involved the sale of 4,331 shares at a weighted average price of $18.5025, with prices ranging from $18.19 to $19.15.
• The second transaction involved the sale of 544 shares at a weighted average price of $19.3979, with prices ranging from $19.245 to $19.49.
• Following the reported transactions, Patel directly owns 2,597 shares and indirectly owns 394,027 shares through The Patel / Dong Family Trust.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock sales by an officer, which is neither particularly positive nor negative.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The Rule 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, depending on their perception of insider selling activity.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates